...
首页> 外文期刊>Journal of immunotherapy >Identification of H-2Db-specific CD8+ T-cell epitopes from mouse VEGFR2 that can inhibit angiogenesis and tumor growth.
【24h】

Identification of H-2Db-specific CD8+ T-cell epitopes from mouse VEGFR2 that can inhibit angiogenesis and tumor growth.

机译:从小鼠VEGFR2鉴定H-2Db特异性CD8 + T细胞表位,可以抑制血管生成和肿瘤生长。

获取原文
获取原文并翻译 | 示例

摘要

Vascular endothelial growth factor receptor 2 (VEGFR2/KDR) plays a crucial role in tumor-associated angiogenesis and vascularization. It has been established that monoclonal antibodies against VEGFR2 can inhibit angiogenesis. In this study, two naturally processed CD8 T-cell epitopes (VILTNPISM and FSNSTNDILI) were identified from murine KDR. Cytotoxic T lymphocytes targeting endothelial cells could be directly monitored by KDR2 and KDR3 Elispots or major histocompatibility complex class I tetramer staining. Immunization with these two peptides effectively reduced angiogenesis and inhibited tumor growth in mouse models. Thus, vaccination with KDR peptides alone or in combination with other anti-angiogenesis agents may afford a novel immunotherapy for inhibition of tumor growth.
机译:血管内皮生长因子受体2(VEGFR2 / KDR)在肿瘤相关的血管生成和血管形成中起着至关重要的作用。已经确定,针对VEGFR2的单克隆抗体可以抑制血管生成。在这项研究中,从鼠KDR中鉴定了两个天然加工的CD8 T细胞表位(VILTNPISM和FSNSTNDILI)。靶向内皮细胞的细胞毒性T淋巴细胞可通过KDR2和KDR3 Elispots或主要组织相容性复合体I类四聚体染色直接监测。在小鼠模型中,用这两种肽免疫可有效减少血管生成并抑制肿瘤生长。因此,单独用KDR肽或与其他抗血管生成剂组合进行疫苗接种可提供抑制肿瘤生长的新型免疫疗法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号